Solventum (NYSE:SOLV) shares rose after hours today on second-quarter results that came in ahead of the consensus forecast.
Shares of SOLV ticked up 2.8% to $73.95 apiece in post-market trading today.
The St. Paul, Minnesota-based 3M Medical spinoff reported profits of $90 million. That equals 51¢ per share on sales of $2.16 billion for the three months ended June 30, 2025.
Solventum recorded a 1.1% bottom-line gain on a sales increase of 3.8%.
Adjusted to exclude one-time items, earnings per share came in at $1.45. That landed 24¢ ahead of expectations on Wall Street. Sales also topped estimates as experts projected $2.12 billion in revenue.
Solventum saw the most growth in Infection Prevention and Surgical Solutions (6.9%), followed by Purification and Filtration (5.4%) and MedSurg (4.8%). Health Information Systems (3.4%), Dental Solutions (2.3%) and Advanced Wound Care (1.7%) followed with growth of their own.
“Our solid second quarter fiscal year 2025 results mark five consecutive quarters of positive sales volume growth since implementing our transformation strategy,” said Bryan Hanson, CEO of Solventum. “Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at the top and bottom line reflecting confidence in our strategy and execution.”
Solventum increased its full-year guidance, now projecting 2%-3% growth, rising from 1.5%-2.5%. It raised its adjusted EPS forecast from $5.45-$5.65 to $5.80 to $5.95.
BTIG analysts Ryan Zimmerman and Iseult McMahon say the post-3M spinoff is “taking flight but not ready to turn off the ‘seatbelt’ sign yet. They maintain a “Neutral” rating but believe they could see modest improvements in the second half of 2025.
“We said investors needed further proof points on SOLV’s ability to execute, and it seems that 2Q25 was a good example of that,” they wrote.
